Cagrilintide research

The Cagrilintide evidence base cited here is 9 sources — 3 clinical, 3 preclinical, 1 review. Its strongest evidence is human — 3 clinical studies, most recently 2025 ("Coadministered Cagrilintide and Semaglutide 2.4 mg in Adults with Obesit…"). Regulatory status: Not FDA-approved (Phase III).

• Cagrilintide (AM833) is a long-acting amylin analog — a dual amylin and calcitonin receptor agonist — developed by Novo Nordisk for weight management, on its own and combined with GLP-1S as 'CagriSema'.
• Reported Phase 3 data for CagriSema describe up to ~22.7% weight loss in obesity (REDEFINE 1) and ~15.7% in type 2 diabetes (REDEFINE 2). These are company/topline-stage figures — confirm against the primary publications before relying on them.
• It is not yet commercially available. Projected approval timing (commonly cited as around 2026) is not confirmed and should be verified.

It is still investigational — not commercially available and not FDA-approved. Several of the figures and timelines below come from company-reported or topline-stage data; where that is the case it is flagged, and those numbers should be confirmed against peer-reviewed publications.

Unlike the GLP-1/GIP/glucagon agonists, cagrilintide works through the amylin pathway, which is why it is complementary to (rather than overlapping with) GLP-1S — the rationale behind the CagriSema combination.

• Anti-cagrilintide antibodies develop in a large share of patients (reported in the ~46–73% range), but have not been reported to reduce efficacy
• No clinically significant QT-interval prolongation was seen in a dedicated thorough-QT study

• REDEFINE 1 (Phase 3 obesity): CagriSema reported ~22.7% mean weight loss at 68 weeks vs placebo — reported figure, confirm against the NEJM publication.
• REDEFINE 2 (Phase 3, type 2 diabetes + obesity): reported ~15.7% weight loss with a large share reaching HbA1c targets — reported figure, confirm against publication.
• Foundational PK/pharmacology: Lau et al., J Med Chem 2021 (characterized the lipidated amylin analog and its ~1-week half-life).

REDEFINE-program figures and any 2026 approval timing were reported topline; treat them as provisional until peer-reviewed publication and an actual regulatory decision.

Cagrilintide is investigational and not approved by the FDA or any regulatory agency; it is not commercially available. Commonly cited approval projections (around 2026) are not confirmed. Research-grade cagrilintide is for laboratory research only and is not intended for human use.

All citations link to the original source (PubMed, journal site, or regulatory filing). Independent research database — no vendor influence on what's cited.